NextCure (NXTC) Q2 Loss Widens 71%
NextCure (NASDAQ:NXTC), a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates and immune medicines for cancer and other diseases, released its second quarter results on August 7, 2025. The report showcased decisive progress in its research and development activities, including the SIM0505 licensing deal and continued advancement of LNCB74 in clinical trials. However, the quarter featured a sharp miss in profitability: GAAP net loss per share was $(11.29), far exceeding analyst expectations for a net loss of $(4.62). GAAP net loss was $26.8 million, compared to $15.4 million a year earlier, mainly due to a one-time $17.0 million license fee. Its pipeline remains on track for key milestones.
Source: Analyst estimates for the quarter provided by FactSet.
NextCure works to develop innovative therapies targeting specific immune system molecules for oncology and rare disease applications. Its lead program, LNCB74, is a B7-H4 antibody-drug conjugate (ADC) for treating solid tumors, which are growths formed by an excess of abnormal cells in tissue. In these ADCs, antibodies are linked to drugs that deliver a powerful treatment to cancer cells with less impact on healthy tissue. LNCB74 is currently in early-stage clinical trials, testing both safety and initial signals of efficacy.
Source Fool.com
